A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792 on ClinicalTrials.gov · last registry update 2026-07-31
An unusually large phase 3: 1,400 participants, more than double the 424 typical for the stage. Due to report August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Number of Participants Allocated to Each Study. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is approved in the US, but not for type 2 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 1,400
- Started
- 2025-05-15
- Primary completion
- 2027-08 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants Allocated to Each Study
Conditions studied
Obesity · Overweight · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.